Abstract
Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Current Pharmaceutical Design
Title: 5-Hydroxytryptamine (5-HT) Receptor Ligands
Volume: 13 Issue: 25
Author(s): Sean L Kitson
Affiliation:
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Abstract: Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Export Options
About this article
Cite this article as:
Kitson L Sean, 5-Hydroxytryptamine (5-HT) Receptor Ligands, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663000
DOI https://dx.doi.org/10.2174/138161207781663000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Menopause, A Universal Female Experience: Lessons from Mexico and Central America
Current Women`s Health Reviews γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Strategies for the Recruitment and Retention of Racial/Ethnic Minorities in Alzheimer Disease and Dementia Clinical Research
Current Alzheimer Research Opinion Paper: Post-surgical Delirium, Consciousness, and Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues
Current Alzheimer Research Editorial [Hot Topic: Multiple Sclerosis – From Bench to Bedside (Guest Editors: Sandra Amor and David Baker)]
CNS & Neurological Disorders - Drug Targets Comprehensive Resources for Tomato Functional Genomics Based on the Miniature Model Tomato Micro-Tom
Current Genomics Impact of DMPEI on Biofilm Adhesion on Latex Urinary Catheter
Recent Patents on Biotechnology Lead (Pb) in Alzheimer’s Dementia: A Systematic Review of Human Case- Control Studies
Current Alzheimer Research Pterostilbene as a Potential Novel Telomerase Inhibitor: Molecular Docking Studies and Its in vitro Evaluation
Current Pharmaceutical Biotechnology Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk
Current Drug Abuse Reviews Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder
Current Pharmaceutical Design Biological Evaluation of Halogenated Thioureas as Cholinesterases Inhibitors Against Alzheimer’s Disease & Molecular Modeling Studies
Letters in Drug Design & Discovery Optimal Pre-treatment for Acute Exposure to the Organophosphate Dicrotophos
Current Pharmaceutical Design The Immunoregulatory Activity of Mesenchymal Stem Cells: ‘State of Art’ and ‘Future Avenues’
Current Medicinal Chemistry Cholinesterase Inhibitory Activity of Some semi-Rigid Spiro Heterocycles: POM Analyses and Crystalline Structure of Pharmacophore Site
Mini-Reviews in Medicinal Chemistry Correlation between Blood and Oral Fluid Psychoactive Drug Concentrations and Cognitive Impairment in Driving under the Influence of Drugs
Current Neuropharmacology Immunosuppression in Sepsis
Current Pharmaceutical Design Recent Advances in Colon Drug Delivery Technology
Drug Delivery Letters Physiotherapy for Ankylosing Spondylitis: Systematic Review and a Proposed Rehabilitation Protocol
Current Rheumatology Reviews